FSK Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
FS KKR Capital Corp is not a good buy right now for a Beginner focused on long-term investing, even with $50,000-$100,000 available. The stock is showing weak technical momentum, negative headline sentiment, and analyst targets have been repeatedly cut. For an impatient investor unwilling to wait for a better entry, this is still not an attractive purchase today.
The technical picture is weak. MACD histogram is negative and still below zero, RSI_6 at 45.99 is neutral but not bullish, and the moving averages are bearish with SMA_200 > SMA_20 > SMA_5, which points to a downtrend. Price at 10.85 is only slightly above pivot 10.814 and below resistance at 11.028, while support sits at 10.6 and 10.468. The stock trend model also suggests near-term weakness over the next week and month.
KKR also highlighted 23% growth in management fee income over the past year, which shows some underlying business strength.
Recent news is negative overall: FS KKR reported Q2 2025 NAV of $21.93 per share, down 6.2% from the prior quarter, and a loss per share of -$0.75, indicating severe financial pressure. There are active class action lawsuits and related allegations about false statements and portfolio restructuring, which hurts sentiment. Analyst targets have been cut repeatedly, reflecting worsening expectations. The stock trend model points to weakness over the next week and month.
The latest reported quarter mentioned in the news is Q2 2025. Financial performance was weak, with net asset value falling 6.2% quarter over quarter to $21.93 per share and EPS at -$0.75. That signals declining asset value and poor earnings quality. The only clear growth note is that management fee income rose 23% year over year, but it is not enough to offset the weaker credit and earnings picture.
Wall Street sentiment is cautious to negative. RBC cut its target to $11 from $13 and kept Sector Perform. Keefe Bruyette cut to $11 from $15 and kept Market Perform. Earlier cuts came from RBC, JPMorgan, Truist, B. Riley, and Keefe Bruyette, showing a consistent downward revision trend. The pros view is that the stock still has some income appeal and operating fee income growth, but the cons dominate: credit impairments, higher funding costs, non-accrual loan concerns, and dividend pressure.
